Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CELU Celularity Inc
- Stocks
- Healthcare
- NASDAQ: CELU
Price (delayed)
$2.04
Market cap
$48.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.64
Enterprise value
$106.72M
Highlights
The gross margin has surged by 144% year-on-year and by 13% since the previous quarter
CELU's revenue has soared by 138% year-on-year and by 12% since the previous quarter
Celularity's EPS has shrunk by 116% QoQ but it has surged by 76% YoY
The company's net income has surged by 71% YoY but it has shrunk by 65% QoQ
CELU's equity has dropped by 78% year-on-year and by 49% since the previous quarter
CELU's debt is up by 5% year-on-year
Key stats
What are the main financial stats of CELU
Market
Valuations
Earnings
Shares outstanding
23.95M
Market cap
$48.86M
Enterprise value
$106.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.19
Price to sales (P/S)
0.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
Revenue
$54.22M
Gross profit
$39.23M
Operating income
-$38.55M
Net income
-$57.89M
EBIT
-$51.63M
EBITDA
-$43.55M
Free cash flow
-$6.56M
Per share
Balance sheet
Liquidity
EPS
-$2.64
EPS diluted
-$2.64
Free cash flow per share
-$0.3
Book value per share
$0.39
Revenue per share
$2.48
TBVPS
$5.3
Total assets
$132.68M
Total liabilities
$123.85M
Debt
$68.84M
Equity
$8.84M
Working capital
-$33.12M
Debt to equity
7.79
Current ratio
0.38
Quick ratio
0.46
Net debt/EBITDA
-1.33
Margins
Efficiency
Dividend
EBITDA margin
-80.3%
Gross margin
72.4%
Net margin
-106.8%
Operating margin
-71.1%
Return on assets
-42.8%
Return on equity
-271.9%
Return on invested capital
-47.4%
Return on capital employed
-65.4%
Return on sales
-95.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CELU stock price
How has the Celularity stock price performed over time
Intraday
2.51%
1 week
22.16%
1 month
24.39%
1 year
-33.11%
YTD
-1.92%
QTD
17.92%
Financial performance
How have Celularity's revenue and profit performed over time
Revenue
$54.22M
Gross profit
$39.23M
Operating income
-$38.55M
Net income
-$57.89M
Gross margin
72.4%
Net margin
-106.8%
Celularity's operating income has plunged by 145% from the previous quarter but it has soared by 87% YoY
The gross margin has surged by 144% year-on-year and by 13% since the previous quarter
CELU's revenue has soared by 138% year-on-year and by 12% since the previous quarter
Celularity's operating margin has shrunk by 117% QoQ but it has surged by 95% YoY
Price vs fundamentals
How does CELU's price correlate with its fundamentals
Growth
What is Celularity's growth rate over time
Valuation
What is Celularity stock price valuation
P/E
N/A
P/B
5.19
P/S
0.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.97
Celularity's EPS has shrunk by 116% QoQ but it has surged by 76% YoY
CELU's equity has dropped by 78% year-on-year and by 49% since the previous quarter
The P/B is 59% less than the 5-year quarterly average of 12.6 but 44% more than the last 4 quarters average of 3.6
CELU's revenue has soared by 138% year-on-year and by 12% since the previous quarter
CELU's P/S is 93% below its 5-year quarterly average of 12.6 and 54% below its last 4 quarters average of 1.8
Efficiency
How efficient is Celularity business performance
The return on equity has dropped by 128% since the previous quarter and by 20% year-on-year
Celularity's return on sales has surged by 89% YoY but it has shrunk by 53% QoQ
CELU's return on invested capital has surged by 72% year-on-year but it has dropped by 70% since the previous quarter
CELU's ROA has dropped by 69% since the previous quarter but it has soared by 50% year-on-year
Dividends
What is CELU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CELU.
Financial health
How did Celularity financials performed over time
CELU's total assets is 7% greater than its total liabilities
Celularity's current ratio has surged by 100% QoQ and by 31% YoY
The quick ratio has surged by 84% since the previous quarter and by 39% year-on-year
The debt to equity has soared by 95% from the previous quarter
CELU's equity has dropped by 78% year-on-year and by 49% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.